| Name | Title | Contact Details |
|---|
RDMD`s mission is to empower patients and communities to accelerate the development of treatments for rare diseases of all kinds.
KalVista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.
Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.
At Cornerstone BioPharma, we are constantly striving to make good medicines better. We know that Healthcare providers and patients are concerned about the safety of today's medications-that makes tried and true medications very appealing. However, due to
Making lives better with natural botanical therapies derived from our patented extraction process